Table 2.
Prospective Clinical Trials For IPL Therapy In DED
| Study (Year) | Design | Patients (n) | IPL Device | Frequency (Weeks) | IPL Sessions (n) | IPL Energy (J/cm2) | Adverse Events | Results |
|---|---|---|---|---|---|---|---|---|
| Ahmed et al (2019)87 | Prospective controlled | 12 | Philips Lumea | / | 1 | 2,5–6,5 | No | Improved tear protein and lipid content and composition |
| Albietz et al (2017)30 | Prospective noncomparative | 26 | E>Eye | 0-2-6 | 3 | 9,8–13 | No | Improved DE symptoms, MG secretion quality, expressibility and ocular surface inflammation |
| Arita et al (2018)22 | Prospective noncomparative | 31 | Lumenis | 3 | 4–8 | 11–14 | / | Improved SPEED, TBUT, CFS and MB parameters |
| Arita et al (2019)21 | Prospective controlled randomized | 45 | Lumenis | 3 | 8 | 11–14 | No | Improved LLT, TBUT, lid margin abnormalities and MGS |
| Choi et al (2019)23 | Prospective noncomparative | 30 | Lumenis | 3 | 3 | 12–14 | No | Improved MG function, tear stability and decreased inflammation (IL-4, IL-6, IL-10, IL-17A, TNF-α) |
| Dell et al (2017)24 | Prospective interventional noncomparative | 40 | Lumenis | 3 | 4 | / | / | Increased TBUT Improved SPEED, MGS, CFS and TFO |
| Guilloto et al (2017)31 | Prospective noncomparative | 36 | E>Eye | 2 | 4 | 8–20 | Redness and light sensitivity | Improved TBUT, Schirmer test and lacrimal meniscus |
| Jiang et al (2016)29 | Prospective | 40 | E>Eye | 0-2-6-10 | 4 | 9,8–13 | No | Improved TBUT, conjunctival injection, symptoms and MG parameters. |
| Karaca et al (2018)85 | Prospective noncomparative | 26 | E>Eye | 0-2-6 | 3 | / | No | Improved TBUT, Schirmer test, OSDI score and SPEED |
| Li et al (2019)25 | Prospective comparative | 40 | Lumenis | 0-2-6 | 3 | 14–16 | Erythema, edema, blister, purpura, hyperpigmentation | Improved TBUT and OSDI score. |
| Seo et al (2018)26 | Prospective noncomparative non-randomized | 17 | Lumenis | 3 | 4 | 11 | No | Long-term improvement of lower lid margin vascularity, meibum expressibility, quality and symptoms. Improved TBUT, CFS. |
| Vigo et al (2019)79 | Prospective noncomparative | 19 | E>Eye | 0-2-6 | 3 | 9–13 | / | Increased TBUT and LLT |
| Yin et al (2017)27 | Prospective comparative | 35 | Lumenis | 4 | 3 | 16–17 | No | Increased TBUT, meibum quality, MG expressibility and dropout. Improved MG microstructure and decreased inflammation |
Abbreviations: DE, dry eye; MG, meibomian glands; TBUT, tear break-up time; SPEED, standard patient evaluation of eye dryness; MGS, meibomian gland score; CFS, corneal fluorescein staining; TFO, tear film osmolarity; LLG, improved lipid layer grade; LLT, lipid layer thickness; OSDI, ocular surface disease index; MGYSS, meibomian gland yielding secretion score.